Italian gene therapy player draws new investor from China for its answer to CAR-T relapses

So you’ve been treated with one of the new-age cancer therapies. What do you do if there’s a relapse and the tumors returns? 

Genenta Science launched four years ago out of Milan in part to answer that question, and today they received $14.4 million in round three funding that will propel their unique gene therapy through Phase I/II trials for multiple myeloma and glioblastoma.